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We measured plasma human immunodeficiency virus type 1
(HIV-1) RNA levels by means of single-copy assay in 334 par-
ticipants receiving virologically suppressive antiretroviral thera-
py (ART). A residual viremia load of ≥1 copy/mL after 4 years
of ART was predicted by a higher pre-ART HIV-1 RNA level,
higher CD8+ T-cell count during treatment, and a lower ratio of
CD4+ T cells to CD8+ T cells during treatment but not by ini-
tial ART regimen. In a longitudinal subset of 64 individuals,
continued decay of the plasma HIV-1 RNA level was observed,
with an average annual decrease of 6% and an estimated half-life
of 11.5 years. In contrast to prior reports, the persistent viremia
level continues to slowly decline during years 4–12 of suppres-
sive ART.
Clinical Trials Registration: NCT00001137.
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Despite long-term suppression of the human immunodeficien-
cy virus type 1 (HIV-1) RNA level below the reportable limit for
Food and Drug Administration (FDA)–approved assays (20–75
copies/mL), antiretroviral therapy (ART) does not eradicate
HIV-1 infection, because of the persistence of infected long-
lived cells. The decay half-life of latently infected memory
CD4+ T-cells has been estimated to be >40 months, requiring
>70 years of ART to eliminate them [1, 2].
Studies have shown that the majority of patients receiving
ART with an HIV-1 RNA level of <50 copies/mL have residual
viremia when tested with a quantitative polymerase chain
reaction (qPCR) assay with single-copy HIV-1 RNA sensitivity
[3–5]. The source of this virus is likely to be long-lived cells that
continually or intermittently express virus that, in most pa-
tients, does not result in ongoing rounds of replication [6].
Prior modeling of the decay in viremia level from week 60 to
week 384 of suppressive ART revealed a biphasic pattern con-
sisting of an initial phase in which decay was observed (half-life,
39 weeks), followed by a plateau phase during which no signifi-
cant decline in the viremia level was detected, suggesting a
half-life of >7 years [4]. The level of persistent viremia has
been correlated with the pre-ART HIV-1 RNA level [3, 4],
but other correlates of residual viremia have yet to be identified.
In the current study, we sought other predictors of persistent
viremia and assessed whether the viremia level decayed in a
large cohort of patients receiving virologically suppressive
ART for up to 12 years.
MATERIALS AND METHODS
Ethics Statement
The AIDS Clinical Trials Group (ACTG) Longitudinal Linked
Randomized Trials (ALLRT) study was a longitudinal cohort
study that prospectively enrolled HIV-1–infected participants
who were participating in randomized ART trials between
1998 and 2011 [7]. An institutional review board at each site ap-
proved the study, and all participants provided written in-
formed consent.
Study Participants
ALLRT participants meeting the following criteria were identi-
fied for this study: initiation of first ART within an ACTG clin-
ical trial (Supplementary Table 1), plasma HIV-1 RNA level
of <50 copies/mL from week 32 of ART until the last available
measurement, and an available cryopreserved plasma specimen
(volume, at least 3 mL) at weeks 192 and 208 of ART. A subset
of these individuals also had additional plasma samples avail-
able for testing at approximately 7, 10, and 12 years after
ART initiation.
Single-Copy HIV-1 RNA Assay
Plasma samples were obtained from ethylenediaminetetraacetic
acid–anticoagulated blood that was collected and processed at
participating ACTG clinical sites between 1998 and 2011; all
plasma samples were stored at −80°C before use in this study.
Plasma samples were tested for HIV-1 RNA at a single labora-
tory between 2011 and 2013, using a single-copy qPCR assay
(SCA) targeting HIV-1 gag. The method and performance
characteristics of the SCA have been previously reported [3,
4]. For the current study, the limit of detection ranged from
0.4 to 1 copy/mL, depending on the plasma volume available.
The amplification efficiency of HIV-1 RNA by SCA was
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determined by testing pretherapy plasma specimens obtained
from participants who had an SCA result of < 1 copy/mL at
both weeks 192 and 208. Participants with pretherapy samples
showing inefficient HIV-1 RNA amplification (<10% amplifica-
tion, compared with the Roche HIV Monitor assay v1.0 or 1.5)
were excluded.
Statistical Analyses
Factors associated with a residual viremia level of ≥1 (vs <1)
copy/mL at weeks 192 and 208 were assessed by odds ratios,
using logistic regression for repeated measures (via generalized
estimating equations). Each subject contributed an observation
at week 192 and at week 208.
Longitudinal decay in the residual viremia level was evaluated
with a random-effects regression model with first-order kinetics
[2], using maximum likelihood methods and estimation
specifically developed to accommodate longitudinal censored
responses (ie, SCA findings of <1 copy/mL) [8]. The correla-
tions between pre-ART HIV-1 RNA level and SCA-results at
weeks 192 and 208 (all log10 transformed) were estimated by
maximum likelihood, using similar censored-data methods [9].
RESULTS
Participant Characteristics
The study population was derived from 3172 ART-naive partic-
ipants from 5 ACTG randomized clinical trials (Supplementary
Table 1). Samples from 405 participants with sufficient available
plasma specimens from weeks 192 and 208 were tested by SCA.
Seventy-one were excluded because of inefficient amplification
efficiency (including 11 with a missing pre-ART plasma speci-
men). The characteristics of the 334 final study participants at
the time of ART initiation and after approximately 4 years of
ART are provided in Supplementary Table 2. The majority
of participants (82%) were male, with a median pre-ART
age of 40 years, a median pre-ART CD4+ T-cell count of
248 cells/mm3, and an HIV-1 RNA level of 4.7 log10 copies/
mL. Initial ART regimens were nonnucleoside reverse tran-
scriptase inhibitors plus nucleoside reverse transcriptase in-
hibitors (NRTIs; 61%), protease inhibitors plus NRTIs (28%),
and other regimens (11%). After 4 years of suppressive ART,
the median CD4+ T-cell count (average of weeks 192 and
208) increased to 588 cells/mm3, and the ratio of CD4+ T
cells to CD8+ T cells increased from 0.29 before ART initiation
to 0.83 after ART initiation.
Predictors of Plasma Viremia Level After 4 Years of ART
The SCA results (668 samples from 334 participants) measured
at weeks 192 and 208 of ART ranged from <0.4 to 41.4 copies/
mL (median, <1 copy/mL; interquartile range, <1 to 2.5). The
SCA result was ≥1 copy/mL at both week 192 and week 208
for 85 subjects (25%) and <1 copy/mL at both weeks for 123
subjects (37%); for the remaining 126 (38%), the SCA result
was ≥1 copy/mL at either week 192 or week 208 and <1
copy/mL at the other week. SCA results at weeks 192 and 208
were significantly correlated (r = 0.46; P < .001). In univariate
repeated-measures analysis, the likelihood of a residual viremia
level of ≥1 copy/mL for the 668 samples tested was predicted by
a higher pre-ART HIV-1 RNA level (odds ratio [OR], 1.79 per 1
log10 [95% confidence interval {CI}, 1.32–2.42]; P < .001), a
higher CD8+ T-cell count during treatment (median average
of weeks 192 and 208, 724 cells/mm3; OR, 1.07 per 100 cells/
mm3 [95% CI, 1.02, 1.12]; P = .008), and a lower ratio of
CD4+ T cells to CD8+ T cells (median, 0.83; OR, 0.72 per 0.5
[95% CI, .58, .90]; P = .004). The initial ART regimen type,
sex, race/ethnicity, injection drug use status, age, CD4+ T-cell
count before or after ART initiation, and pre-ART CD8+ T-cell
count or ratio of CD4+ T cells to CD8+ T cells were not associ-
ated with residual viremia (all P > .05; Table 1).
After adjustment for pre-ART HIV-1 RNA load, a higher av-
erage CD8+ T-cell count and a lower ratio of CD4+ T cells to
CD8+ T cells at weeks 192 and 208 remained significant predic-
tors of a plasma HIV-1 RNA load of ≥1 copy/mL (P = .014 and
P = .031, respectively). The pretherapy HIV-1 RNA load was
significantly associated with week 192 and week 208 SCA results
(r = 0.18 [P = .004] for week 192 and 0.20 [P = .001] for week
208).
Longitudinal Assessment of Residual Viremia
For 64 participants, SCA was performed on an additional 2–4
plasma specimens (median, 3 specimens) obtained at 2–3-
year intervals after week 208 (Supplementary Table 3). In
this longitudinal cohort, the median interval from the time
of ART initiation to the time when plasma HIV-1 RNA was
last measured by SCA was 11.2 years (minimum interval, 8.1
years). Participants with persistent viremia during year 4
(SCA result, ≥1 copy/mL at both week 192 and week 208)
generally had a viremia level of ≥1 copy/mL at years 7 and
10 (65% and 56%, respectively); by contrast, participants
with undetectable viremia during year 4 rarely had a viremia
level of ≥1 copy/mL at years 7 and 10 (14% and 9%, respec-
tively). The distribution of the plasma HIV-1 RNA load by
year after ART initiation for all 64 participants is provided
in Figure 1A. Using a random-effects repeated-measures re-
gression model developed for censored assay data, there was
evidence of a decay in SCA levels over time (P = .023), estimat-
ed to be 0.026 log10 per year. This decay corresponds to a 6%
decline in the plasma HIV-1 RNA level per year and an esti-
mated half-life of 11.5 years (95% CI, 6.2–83). The rate of
decay was similar for the 27 subjects with a SCA result of
≥1 copy/mL at week 192 (Figure 1B).
DISCUSSION
In the large, cross-sectional component of this study, the pres-
ence of measurable residual viremia (≥1 copy/mL) after ap-
proximately 4 years of suppressive ART was predicted by a
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higher pre-ART HIV-1 RNA level, a higher CD8+ T-cell count
during treatment, and a lower ratio of CD4+ T cells to CD8+ T
cells during treatment. The pre-ART HIV-1 RNA level has pre-
viously been associated with the level of persistent viremia, but
the CD8+ T-cell count during treatment and a lower ratio of
CD4+ T cells to CD8+ T cells during treatment have not,
which provides new clues into the mechanisms underlying per-
sistent viremia. Key factors that were not associated with persis-
tent viremia in well-powered analyses were age, sex, race/
ethnicity, ART regimen, pre-ART CD4+ T-cell count, pre-
ART CD8+ T-cell count, and pre-ART ratio of CD4+ T cells
to CD8+ T cells.
Importantly, in the longitudinal cohort followed for a median of
11.2 years, a significant decay in the plasma HIV-1 RNA level was
observed. This result provides the first evidence of slow but ongo-
ing decay of the plasma viremia level after 4 years of suppressive
ART. The decay in the viremia level occurred with an estimated
half-life of 11.5 years and a wide CI (95% CI, 6.2–83). The statis-
tical approach to assess decay in our study was robust and ad-
dressed the issue of assay censoring by use of longitudinal
statistical models developed to address this issue [8]. The larger
size and longer follow-up in the current study, compared with
prior ones, is likely to have increased the power to detect decay.
A more precise estimate of the decay rate for the plasma viremia
level would require a larger sample size and longer-term follow up.
The estimate for the rate of ongoing decay of plasma vire-
mia level demonstrated by our data was very small (0.026 log10
per year), indicating that the plasma viremia level measured
by SCA is a valid end point to assess changes in viremia
level after short-term experimental interventions to enhance
viral expression from latent proviruses or to deplete HIV-1
reservoirs. The estimated half-life of 11.5 years for the
plasma viremia level during suppressive ART is longer than the
reported estimate of 3.7 years (95% CI, 2.3–9.5) for the half-
life of the latent, infectious viral reservoir in resting CD4+
T cells, but both estimates have broad and overlapping CIs [2].
The cellular sources and mechanisms of persistent viremia
during long-term suppressive ART are still undefined. Ongoing
viral replication is unlikely to be a common source of residual
viremia, based on the lack of impact of ART intensification [10]
and the lack of evolution in the rebounding virus population
after ART interruption, compared with the pre-ART virus
population [6]. Persistent viremia from clonal expansion of
HIV-1–infected cells in individuals receiving suppressive ART
has recently been described, but the frequency of this phenom-
enon needs to be better defined [11, 12].
In prior studies, no association has been demonstrated be-
tween the level of residual viremia and the degree of immune
activation [10, 13]. In the current study, we demonstrated that
a lower ratio of CD4+ T cells to CD8+ T cells during ART
was associated with greater likelihood of persistent viremia. Ser-
rano-Villar et al have shown that a lower ratio of CD4+ T cells to
CD8+ T cells during effective ART was associated with higher
immune activation (ie, an increased percentage of CD38+DR+
Table 1. Predictors of a Residual Viremia Level of ≥1 copy/mL 192 and 208 Weeks After Antiretroviral Treatment (ART) Initiation
Predictor Observations, No.a
Unadjusted Adjustedb
OR (95% CI) P Value OR (95% CI) P Value
Pre-ART HIV-1 RNA level (log10 copies/mL) 668 1.79 (1.32–2.42) <.001
Pre-ART CD4+ T-cell count (per 100 cells/mm3) 668 0.91 (.83–1.00) .053 0.98 (.89–1.08) .63
Pre-ART CD8+ T-cell count (per 100 cells/mm3) 668 1.01 (.98–1.05) .45 1.02 (.99–1.06) .21
Pre-ART ratio of CD4+ to CD8+ T cells (per 0.5 increase) 668 0.71 (.37–1.36) .30 0.83 (.56–1.22) .34
Age at parent study entry (per 10 y) 668 1.09 (.92–1.29) .35 1.07 (.90–1.28) .41
CD4+ T-cell count during treatmentc (per 100 cells/mm3) 664 0.99 (.92–1.07) .88 1.02 (.95–1.10) .53
CD8+ T-cell count during treatmentc (per 100 cells/mm3) 664 1.07 (1.02–1.12) .008 1.06 (1.01–1.11) .014
Ratio of CD4+ to CD8+ T cells during treatmentc (per 0.5 increase) 664 0.72 (.58–.90) .004 0.78 (.63–.98) .031
Female sex (vs male sex) 668 0.70 (.44–1.11) .13 0.69 (.44–1.10) .12
Initial ART regimen 668
PIs + NRTIs (vs NNRTIs + NRTIs) 1.16 (.79–1.71) .45 1.30 (.88–1.92) .19
Other (vs NNRTIs + NRTIs) 1.06 (.60–1.87) .83 1.03 (.58–1.85) .91
Race/ethnicity 668
Hispanic (vs white non-Hispanic) 0.89 (.57–1.39) .60 0.91 (.58–1.42) .68
Black non-Hispanic (vs white) 0.79 (.52–1.20) .26 0.83 (.54–1.28) .41
Other (vs white) 1.17 (.31–4.39) .82 1.21 (.31–4.84) .78
Past history of injection drug use (vs no history) 668 1.08 (.56–2.07) .82 1.13 (.59–2.18) .71
Abbreviations: CI, confidence interval; HIV-1, human immunodeficiency virus type 1; NNRTI, nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; OR,
odds ratio; PI, protease inhibitor.
a There were 2 values per participant, unless otherwise indicated.
b Analyses were adjusted for pre-ART HIV-1 RNA level.
c Data are for 332 participants (2 values per participant) and reflect the average of values at weeks 192 and 208.
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CD8+ T cells) and immune senescence (ie, an increased number
of CD57+CD28− T cells) [14]. Whether residual viremia is a
cause or consequence of a lower ratio of CD4+ T cells to
CD8+ T cells requires further investigation, including analysis
of interventions that affect residual viremia, T-cell reconstitu-
tion, or persistent immune activation.
This study has some limitations. The ART regimens used by
the participants did not include integrase inhibitors or other
more recently approved drugs. Additionally, the gag SCA used
has higher rates of inefficient HIV-1 RNA amplification due to
primer mismatch, compared with the recently optimized SCA
targeting integrase [15]. However, individuals with inefficient
amplification by gag SCA were, appropriately, excluded. Finally,
the study is limited by the lack of simultaneous data on immune
activation and systemic inflammation, and data on cellular reser-
voirs including blood and tissues were not available.
Nevertheless, this study shows that the persistent viremia
level decays gradually over time and suggests that cells capable
of expressing HIV-1 do not persist indefinitely. Interventions
to accelerate the death of HIV-1–producing cells should be
vigorously pursued, including monoclonal antibodies, thera-
peutic vaccinations, latency reversal agents, and immune
checkpoint inhibitors, and should include measurement of
the persistent viremia level as an indicator of response.
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